Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group.

[1]  D. Vidt,et al.  Effects of losartan versus captopril on mortality in patients with symptomatic heart failure , 2000 .

[2]  K. Dickstein,et al.  Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II. , 1999, Journal of cardiac failure.

[3]  J. Cohn,et al.  Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. , 1999, Journal of cardiac failure.

[4]  R. McKelvie,et al.  Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. , 1997, Journal of the American College of Cardiology.

[5]  K. Dickstein,et al.  Effects of angiotensin II receptor blockade on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure. , 1997, Journal of cardiac failure.

[6]  C. Ferrario,et al.  Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries. , 1997, The Journal of pharmacology and experimental therapeutics.

[7]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[8]  S. Howlett,et al.  Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion. , 1996, The Journal of pharmacology and experimental therapeutics.

[9]  T. Buclin,et al.  Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers. , 1996, Kidney international. Supplement.

[10]  K. Dickstein,et al.  Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. , 1995, Journal of the American College of Cardiology.

[11]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[12]  K. Dickstein,et al.  Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. , 1995, Circulation.

[13]  C. Sweet,et al.  Losartan in heart failure: preclinical experiences and initial clinical outcomes. , 1994, European heart journal.

[14]  D. Ganten,et al.  Widespread tissue distribution of human chymase. , 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[15]  Hiroaki Tanaka,et al.  Angiotensin II formation by an alternative pathway during exercise in humans , 1994, Journal of hypertension.

[16]  M. Burnier,et al.  Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. , 1993, Hypertension.

[17]  P. Timmermans,et al.  Angiotensin II receptors and angiotensin II receptor antagonists. , 1993, Pharmacological reviews.

[18]  T. Baussant,et al.  Angiotensin‐Converting Enzyme Inhibition Does Not Suppress Plasma Angiotensin II Increase During Exercise in Humans , 1993, Journal of cardiovascular pharmacology.

[19]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[20]  J. Boissel,et al.  Relative efficacy of angiotensin converting enzyme inhibitors on mortality of patients with congestive heart failure: implications of randomized trials and role of the aetiology (ischaemic or non-ischaemic) of heart failure. , 1992, European heart journal.

[21]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[22]  K. Misono,et al.  Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. , 1990, The Journal of biological chemistry.

[23]  S Greenland,et al.  Bias in the one-step method for pooling study results. , 1990, Statistics in medicine.

[24]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[25]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .